A 239-query cross-sectional survey was sent out by means of e-mail in January 2017 to collect extensive information and facts on cannabis use from Canadian health-related cannabis patients registered with a federally authorized licensed cannabis producer, resulting in 2032 full surveys.
The survey gathered detailed demographic information and extensive information and facts on patient patterns of health-related cannabis use, which includes concerns assessing the self-reported influence of cannabis on the use of prescription drugs, illicit substances, alcohol, and tobacco.
Participants had been 62.six% male (n = 1271) and 91% Caucasian (n = 1839). The imply age was 40 years old, and discomfort and mental well being circumstances accounted for 83.7% of all respondents (n = 1700). Then, 74.six% of respondents reported daily cannabis use (n = 1515) and imply quantity made use of per day was 1.5 g. The most typically cited substitution was for prescription drugs (69.1%, n = 953), followed by alcohol (44.five%, n = 515), tobacco (31.1%, n = 406), and illicit substances (26.six%, n = 136). Opioid drugs accounted for 35.three% of all prescription drug substitution (n = 610), followed by antidepressants (21.five%, n = 371). Of the 610 mentions of precise opioid drugs, sufferers report total cessation of use of 59.three% (n = 362).
This study provides a one of a kind point of view by focusing on the use of a standardized, government-regulated supply of health-related cannabis by sufferers registered in Canada’s federal health-related cannabis program. The findings give a granular view of patient patterns of health-related cannabis use, and the subsequent self-reported impacts on the use of opioids, alcohol, and other substances, adding to a expanding physique of academic investigation suggesting that elevated regulated access to health-related and recreational cannabis can outcome in a reduction in the use of and subsequent harms related with opioids, alcohol, tobacco, and other substances.